Individualized Immunotherapy: ctDNA Monitoring Provides Real-time Signal of Clinical Benefit in Cancer Patients

Time: 9:15 am
day: Day Two


• A comprehensive ctDNA monitoring assay (tumor-informed and naïve design) was developed and deployed for parallel evaluation of neoantigen dynamics, tumor evolution and molecular response (MR) in phase 1/2 clinical trials of Gritstone’s individualized immunotherapy for solid tumors (GRANITE)
• In an end-stage MSS-CRC patient cohort, MR was associated with extended overall survival
• GRANITE has advanced into a randomized, controlled phase 2/3 clinical trial in newly-diagnosed metastatic MSS-CRC patients– ctDNA response is the primary efficacy endpoint of phase 2 trial component and will be prospectively correlated with OS